Core Viewpoint - Purcell & Lefkowitz LLP is investigating Cineverse Corp. to determine if its directors breached fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is on behalf of Cineverse Corp.'s shareholders [1]. - Shareholders interested in their rights and options can contact Purcell & Lefkowitz LLP for more information [2]. - Purcell & Lefkowitz LLP specializes in representing shareholders affected by securities fraud and corporate misconduct [3].

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, impacting investors who purchased its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, with its primary drug candidate being sonelokimab (SLK) [3]. Allegations - The lawsuit claims that MoonLake made false or misleading statements regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, which is an FDA-approved monoclonal antibody for the same condition [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide superior clinical benefits or efficacy [4]. Stock Performance Impact - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, which indicated SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who suffered losses during the class period can seek to become lead plaintiffs in the lawsuit, with a deadline for motions set for December 15, 2025 [2][6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - DJS Law Group is investigating Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding a clinical study [1][2]. Investigation Details - The investigation centers on Larimar's September 29, 2025 announcement of an open-label study involving daily subcutaneous injections of Nomlabofusp for Friedreich's Ataxia, which was presented as having positive results despite severe allergic reactions experienced by multiple participants [2]. - Following the release of this information, Larimar's shares experienced a significant decline of 33.66% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Larimar Therapeutics, Inc. following the announcement of adverse reactions in a clinical study, which led to a significant drop in the company's stock price [1][2]. Summary by Sections Investigation Details - The investigation centers on whether Larimar Therapeutics made false or misleading statements or failed to disclose critical information to investors [2]. - On September 29, 2025, Larimar reported data from an ongoing study of Nomlabofusp for Friedreich's Ataxia, claiming positive results while also revealing that seven participants experienced severe allergic reactions or anaphylaxis [2]. Market Reaction - Following the announcement of the study results and the adverse reactions, Larimar's shares fell by over 33.6% on the same day [2].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of WPP plc, covering the period from February 27, 2025, to July 8, 2025, due to allegations of misleading statements regarding the company's media arm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that WPP plc provided overwhelmingly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges, leading to a loss of market share [5]. - Investors who purchased WPP plc ADSs during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Group 1 - Halper Sadeh LLC is investigating TrueCar, Inc. for potential violations related to its sale to Fair Holdings, Inc. at $2.55 per share [1] - Hillenbrand, Inc. is under investigation for its sale to an affiliate of Lone Star Funds for $32.00 per share in cash [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options without any out-of-pocket payment for legal fees [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, impacting investors who purchased its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Allegations - The lawsuit claims that during the class period, MoonLake made false or misleading statements regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for HS [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide superior clinical benefits or efficacy [4]. Stock Performance Impact - Following the announcement of disappointing Phase 3 VELA program results on September 28, 2025, which indicated SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased MoonLake common stock during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history at $7.2 billion in the Enron case [7].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit for securities fraud, alleging that the company made false and misleading statements regarding its drug candidate, sonelokimab (SLK), which led to significant losses for investors [4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against MoonLake Immunotherapeutics for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased securities between March 10, 2024, and September 29, 2025, are encouraged to contact the firm before December 15, 2025 [2]. - The lawsuit claims that MoonLake misled the market about the superiority of SLK over other monoclonal antibodies, despite lacking proven advantages [4]. Group 2: Impact on Investors - Following the announcement of a Phase 3 trial result deemed "disastrous" by analysts, MoonLake's shares lost almost 90% of their value [4]. - The company's public statements were characterized as false and materially misleading throughout the class period, resulting in damages for investors when the truth was revealed [4].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Summary by Relevant Sections Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, which could jeopardize PYLARIFY's price point and revenue growth [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative of the class or may choose to remain absent [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Marex Group PLC is facing a class action lawsuit due to allegations of accounting fraud and misleading financial disclosures, with a deadline for investors to file a lead plaintiff motion by December 8, 2025 [1][5]. Summary by Sections Allegations and Findings - A report by NINGI Research on August 5, 2025, accused Marex of engaging in a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits [3]. - Specific allegations include a $17 million receivable created without basis, a subsidiary's profit inflated by 150% before liquidation, and a $14.9 million asset sold to Robinhood for only $2.5 million [3]. - The report also claimed Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, misclassifying structured note issuance as income to inflate cash flow [3]. Stock Market Reaction - Following the allegations, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, with unusually high trading volume [4]. Lawsuit Details - The class action lawsuit alleges that Marex made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period from May 16, 2024, to August 5, 2025 [5]. - Key points of the lawsuit include the sale of over-the-counter financial instruments to itself, inconsistencies in financial statements, and the unreliability of Marex's financial disclosures [5]. Participation Information - Investors who purchased Marex securities during the class period can file a motion to be appointed as lead plaintiff by the deadline of December 8, 2025 [6].